       Document 0787
 DOCN  M95A0787
 TI    Anti-Human T-lymphotropic virus type-I antibodies in atomic-bomb
       survivors.
 DT    9510
 AU    Matsuo T; Nakashima E; Carter RL; Neriishi K; Mabuchi K; Akiyama M;
       Shimaoka K; Kinoshita K; Tomonaga M; Ichimaru M; Department of Clinical
       Studies, Nagasaki Central Hospitals.
 SO    J Radiat Res (Tokyo). 1995 Mar;36(1):8-16. Unique Identifier : AIDSLINE
       MED/95341594
 AB    Adult T-cell leukemia (ATL), induced by human T- lymphotropic virus
       type-I (HTLV-I), is endemic in Nagasaki, Japan. To investigate the
       effects of atomic-bomb radiation on development of this specific type of
       leukemia, 6182 individuals in the Radiation Effects Research Foundation
       (RERF) Adult Health Study sample in Hiroshima and Nagasaki were examined
       for positive rate of HTLV-I antibody. Several lymphocyte parameters were
       also studied for 70 antibody- positive subjects in Nagasaki. The HTLV-I
       antibody-positive rate was higher in Nagasaki (6.36%) than in Hiroshima
       (0.79%) and significantly increased with increasing age, but no
       association was observed with radiation dose. Whether relationship
       existed between antibody titer levels and radiation dose among
       antibody-positive subjects was not The frequency of abnormal lymphocytes
       tended to be higher in antibody-positive subjects than in
       antibody-negative subjects, and higher in females than in males
       regardless of radiation dose. The lymphocyte count was lower in
       antibody-positive subjects than in antibody-negative subjects and lower
       in female than in male subjects. No evidence was found to suggest that
       atomic-bomb radiation plays an important role in HTLV-I infection.
 DE    Adult  Aged  Aged, 80 and over  Female  Human  HTLV-I
       Antibodies/*ANALYSIS  HTLV-I Infections/EPIDEMIOLOGY  Japan/EPIDEMIOLOGY
       Male  Middle Age  *Nuclear Warfare  Radiation Dosage  Support, Non-U.S.
       Gov't  Support, U.S. Gov't, Non-P.H.S.  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

